A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib withendocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer
- Conditions
- hormone receptor-positive, HER2-negative, early breast cancerMedDRA version: 20.0Level: LLTClassification code 10006203Term: Breast cancer stage unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2018-002998-21-DE
- Lead Sponsor
- ovartis Pharma AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 5000
- Patient is = 18 years-old at the time of PICF signature
- Patient is female with known menopausal status at the time of randomization or initiation of adjuvant ET (whichever occurs earlier), or male.
- Patient with histologically confirmed unilateral primary invasive adenocarcinoma of the breast with a date of initial cytologic or histologic diagnosis (i.e. date of the pathology report that confirmed the BC diagnosis) within 18 months prior to randomization.
- Patient has breast cancer that is positive for ER and/or PgR
- Patient has HER2-negative breast cancer
- Patient has available archival tumor tissue from the surgical specimen
- Patient after surgical resection where tumor was removed completely, with the final surgical specimen microscopic margins free from tumor, and who belongs to one of the following categories (anatomic stage group II or III)
- If indicated, patient has completed adjuvant and/or neoadjuvant chemotherapy according to the institutional guidelines
- If indicated, patient has completed adjuvant radiotherapy according to the institutional guidelines
- Patient has no contraindication for the adjuvant
ET in the trial and is planned to be treated with ET for 5 years
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 4245
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 755
- Patient has received any CDK4/6 inhibitor
- Patient has received prior treatment with tamoxifen, raloxifene or AIs for reduction in risk (chemoprevention) of breast cancer and/or treatment for osteoporosis within the last 2 years prior to randomization. Patient is concurrently using hormone replacement
therapy.
- Patient has received prior treatment with anthracyclines at cumulative doses of 450 mg/m² or more for doxorubicin, or 900 mg/m² or more for
epirubicin.
- Patient with a known hypersensitivity to any of the excipients of ribociclib and/or ET
- Patient with distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery.
- Patient is concurrently using other anti-neoplastic therapy with the exception of adjuvant ET
- Patient has had major surgery, chemotherapy or radiotherapy within 14 days prior to randomization
- Patient has not recovered from clinical and laboratory acute toxicities related to prior anti-cancer therapies
- Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 2 years before randomization
- Patient has known HIV infection, Hepatitis B or C infection
- Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
- Patient is currently receiving any of the following substances within 7 days before randomization - Concomitant medications, herbal supplements, and/or fruits that are known as strong inhibitors or inducers of CYP3A4/5 or Medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5
- is currently receiving or has received systemic corticosteroids = 2 weeks prior to starting trial treatment
- Patient has impairment of GI function or GI disease that may significantly alter the absorption of the oral trial treatments
- Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator’s judgment, cause unacceptable safety
risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol
- Participation in other studies involving investigational drug(s) within 30 days prior to randomization or within 5 half-lives of the
investigational drug(s) (whichever is longer), or participation in any
other type of medical research judged not to be scientifically or
medically compatible with this trial. If the patient is enrolled or planned to be enrolled in another study that does not involve an investigational drug, the agreement of the Medical Monitor is required to establish eligibility.
- Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial.
additional exclusion criteria as per full protocol may apply.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To compare iDFS for ribociclib + ET versus ET in patients with HRpositive, HER2-negative, EBC;Secondary Objective: 1. To evaluate the two treatment arms with respect to recurrence-free survival (RFS)<br>2. To evaluate the two treatment arms with respect to distant diseasefree survival (DDFS)<br>3. To evaluate the two treatment arms with respect to OS<br>4. To evaluate patient reported outcomes (PRO) for health-related quality of life (QoL) in the two<br>treatment arms<br>5. To characterize the PK of ribociclib when given in combination with NSAI (and goserelin if applicable);Primary end point(s): iDFS using STEEP criteria, as assessed by Investigator;Timepoint(s) of evaluation of this end point: up to approximately 44 months
- Secondary Outcome Measures
Name Time Method Secondary end point(s): - recurrence free survival (RFS) using STEEP criteria<br>(Standardized Definitions for Efficacy End Points in<br>Adjuvant Breast Cancer Trials)<br>- Distant disease free survival (DDFS) using STEEP criteria (Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials)<br>- overall survival (OS)<br>- Change from baseline in the physical functioning subscale score and global health status/Quality of life scale score as assessed by EORTC QLQ-C30<br>- PK parameters such as Ctrough and other applicable parameters for ribociclib;Timepoint(s) of evaluation of this end point: -up to approximately 44 months<br>-up to approximately 44 months<br>-up to approximately 91 months<br>-up to approximately 44 months<br>-up to approximately 44 months